Page 2 - Immunization Study News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Immunization Study. Real-time updates on events, politics, business and more.

The maternal RSV vaccine from Pfizer protects newborns against severe illness

November 2, 2022

Pfizer announced its maternal vaccine against RSV to be almost 82% effective in protecting infants for the first 90 days of life against severe illness.

United States Blanscape Shutterstock United States National Institutes Of Health Lab Diagnostics Automation Lab Diagnostics Automation Industry Pfizer Announces Positive Top Line Data

Source: news-medical.net

Pfizer Reports Positive Top-Line Trial Data For Bivalent RSV Vaccine Candidate

November 1, 2022

NEW YORK CITY (dpa-AFX) - Drug major Pfizer Inc. (PFE) announced Tuesday positive top-line data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus or RSV

Pfizer Inc Drug Administration Data Monitoring Committee More Such Health News Maternal Immunization Trial Bivalent Respiratory Syncytial Virus

Source: finanznachrichten.de

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Page 2 - Immunization Study News Today

The maternal RSV vaccine from Pfizer protects newborns against severe illness

Pfizer Reports Positive Top-Line Trial Data For Bivalent RSV Vaccine Candidate

Explore More Categories